Artificial Intelligence and clinical research: which issues remain?


This issue is discussed in the new article written under the direction of Vincent Diebolt, Director of the French Clinical Research Infrastructure Network (F-CRIN), entitled “Artificial Intelligence”: which services, which applications, which results and which development today in clinical research? Which impacts on the quality of care? Which recommendations?, published at the end of 2018.

The articles discusses the potential of artificial intelligence (AI) to process numerous and heterogenous data and knowledge and to understand potentially complex and abstract rules in the same way as human intelligence can. In particular, it outlines how experts confirmed the potential contribution and theoretical benefits of AI in healthcare such as in clinical research and patient care efficiency.

It identifies critical points how AI benefits could be maximized:

  1. Production of tangible demonstrations of the contributions of AI in clinical research by quantifying its benefits;
  2. Building trust to foster dissemination and acceptability of AI in healthcare thanks to an adapted regulatory framework;
  3. Ensuring the availability of technical skills, which implies an investment in training, the attractiveness of the health sector relative to tech-heavy sectors and the development of ergonomic data collection tools for all health operators;
  4. Organisation of a system of governance for a distributed and secure model at the national level to aggregate the information and services existing at the local level.

These four points need to be examined closely as they condition the technical integration and appropriation of AI by all actors of the life science spectrum. As a result, 37 concrete recommendations are presented to enable the adoption of AI in clinical research.

Among the co-authors who contributed to this article, Avicenna Alliance is proud to count François-Henri Boissel (Novadiscovery), Avicenna Board Member. The Alliance also pleased to note that Avicenna’s General Secretary, Thierry Marchal (ANSYS), participated in the Giens XXXIV round table ‘Hot topic N°2’ which contributed to the publication of this article.